Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiselimod in Systemic Lupus Erythematosus
NCT02307643Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Feb 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amiselimod in systemic lupus erythematosus (SLE) (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Number of Subjects with Adverse Events at 36 weeks. Started Feb 2015; status: completed.
02
Drugs
amiselimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02307643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307643.